The effect of atypical antipsychotic agents on prolactin levels in children and adolescents

Journal of Child and Adolescent Psychopharmacology

Volumn 14, Issue 3, 2004, Pages 359-371

  Pappagallo, Mia ^a   Silva, Raul ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

ADOLESCENT; AGE; BODY WEIGHT DISORDER; BONE DENSITY; CHILD; CHILD PSYCHIATRY; DISEASE ASSOCIATION; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; MEDICAL LITERATURE; OSTEOPOROSIS; PROLACTIN BLOOD LEVEL; REVIEW; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; PROLACTIN;

EID: 8144221426     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2004.14.359     Document Type: Review

References (58)

1. Alfaro CL, Wudarsky M, Nicolson R, Gochman P, Sporn A, Lenane M, Rapoport JL: Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol 12(2):83-91, 2002.
2. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, Risperidone Disruptive Behavior Study Group: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346, 2002.
3. Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M: Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients J Clin Psychiatry 64:761-766, 2003.
4. Bunker MT, Marken PA, Schneiderhan ME, Ruehter VL: Attenuation of antipsychotic-induced hyperprolactinemia with clozapine J Child Adolesc Psychopharmacol 7:65-69, 1997.
5. Cesena M, Gonzalez-Heydrich J, Szigethy E, Kohlenberg TH, De Maso DR: A case series of eight aggressive young children treated with risperidone. J Child Adolesc Psychopharmacol 12:337-345, 2002.
6. Cohen L, Biederman J: Case report: Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol 11:435-440, 2001.
7. Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, Pietrosante M, Salvatore M, Lombardi G: Prolactinomas in adolescents: Persistent bone loss after two years of prolactin normalization. Clin Endocrinol 52:319-327, 2000.
8. Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G: Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrin Metab 83:2777-2780, 1998.
9. Conley R, Meltzer H: Adverse events related to olanzapine. J Clin Psychiatry 61(Suppl):26-29, 2000.
10. Crawford AM, Beasley CM Jr, Tollefson GD: The acute and long-term effects of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 26:41-54, 1997.
11. Csermely T, Halvax L, Schmidt E, Zambo K, Vadon G, Szabo I, Szilagyi A: Occurrence of osteopenia among adolescent girls with oligo/amenorrhea. Gynecol Endocrinol 16:99-105, 2002.
12. Dickson RA, Glazer WM: Neuroleptic-induced hyperprolactinemia. Schizophr Res 35(Suppl):S75-S86, 1999.
13. Di Somma C, Colao A, Di Sarno A, Klain M, Landi, ML, Facciolli F, Pivonello R, Panza N, Salvatore M, Lombardi G: Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 83(3):807-814, 1998.
14. Dissaneevate P, Warne GL: Hyperprolactinemia and pituitary adenomas in adolescence. J Ped Endocrinol Metab 11(4):531-548, 1998.
15. Duntas L: Prolactinomas in children and adolescents - consequences in adult life J Ped Endocrinol Metab 14:1227-1232, 2001.
16. Fideleff HL, Ruibal G, Boquete H, Pujol A, Sequera A, Sobrado P: Macroprolactinemia in childhood and adolescence: A cause of asymptomatic hyperprolactinemia Horm Res 53:16-19, 2000.
17. Findling RL, McNamara NK, Youngstrom EA, Branicky LA, Demeter CA, Schulz SC: A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 42:170-175, 2003.
18. Frazier JA, Meyer MC, Biederman J, Wozniak J, Wilens TE, Spencer TJ, et al: Risperidone treatment for juvenile bipolar disorder: A retrospective chart review. J Am Acad Child Adolesc Psychiatry 38:960-965, 1999.
19. Galli-Tsinopoulou A, Nousia-Arvanitakis S, Mitsiakos G, Karamouzis, Dimitriadis A: Osteopenia in children and adolescents with hyperprola-tinemia. J Pediatr Endocrinol Metab 13:439-441, 2000.
20. Goodnick PJ, Rodriquez L, Santana O: Anti-psychotics: Impact on prolactin levels. Expert Opin Pharmacother 3:1381-1391, 2002.
21. Gordon CM, Nelson LM: Amenorrhea and bone health in adolescents and young women. Curr Opin Obstetrics Gynecol 15:377-384, 2003.
22. Gupta S, Bradford F, Madhusoodanan, S: Risperidone-associated galactorrhea in a male teenager [Letter to the editor] J Am Acad Child Adolesc Psychiatry 40:504-505; 2001.
23. Hamner MB, Arana GW: Hyperprolactinemia in antipsychotic-treated patients. CNS Drugs 10:209-222, 1998.
24. Henry JM, Filburn CR, Joseph JA, Roth GS: Effect of aging on striatal dopamine receptor subtypes in Wistar rats. Neurobiol Aging 7:357-361, 1986.
25. Holford L, Peter E, van der Walt A: Risperidone for behavior disorders in children with mental retardation, preliminary data. Presented at the 47th annual meeting of the AACAP, October 24-29, 2000.
26. Holtmann M, Gerstner S, Schmidt MH: Risperidone-associated ejaculatory and urinary dysfunction in male adolescents J Child Adolesc Psychopharmacol 13:107-109, 2003.
27. 2 receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Brain Res Molec Brain Res 55:285-292, 1998.
28. Jordan MP: Ziprasidone-associated galactorrhea in a female teenager. J Am Acad Child Adolesc Psychiatry 42:4-5, 2003.
29. Kamel N, Uysal AR, Cesur V, Erogan G, Baskai N: Normal growth and puberty development during bromocriptine therapy in two patients with prolactinoma. Endocrine J 42:581-586, 1995.
30. Kane JM, Carson WH, Saha AR McQuade RD, Ingenito GG, Zimbroff DL, Ali MW: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763-771, 2002.
31. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286-293, 1999.
32. 2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia Am J Psychiatry 157:514-520, 2000.
33. 2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 158:311-314, 2001.
34. Kawano Y, Kamihigashi S, Nakamura S, Miyakawa I: Delayed puberty associated with hyperprolactinemia caused by pituitary microadenoma Arch Gynecol Obstet 264:90-92, 2000.
35. Kayath MJ, Lengyel AMJ, Vieira JGH: Prevalence and magnitude of osteopenia in patients with prolactinoma. Brazilian J Med Biol Res 26:933-941, 1993.
36. Keller R, Mongini F: Switch to quetiapine in antipsychotic agent-related hyperprolactinemia. Neurol Sci 23:233-235, 2002.
37. Kleinberg DL, Davis JM, deCoster R, Van Baelen B, Brecher M: Prolactin levels and adverse events in patients treated with risperidone [Brief reports] J Clin Psychopharmacol 19:57-61, 1999.
38. Masi G, Cosenza A, Mucci M: Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharm 11:389-394, 2001.
39. McConville BJ, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 61:252-260, 2000.
40. Meltzer, HY: The mechanism of action of novel antipsychotic drugs: Schizophr Bull 17:263-287, 1991.
41. Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS: Effect of clozapine on human serum prolactin levels. Am J Psychiatry 136:1550-1555, 1979.
42. Meltzer HY, Matsubara S, Lee JC: The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25:390-392, 1989.
43. Perry RI, Pataki C, Munoz-Silva D, Armenteros JL, Silva R: Risperidone in children and adolescents with pervasive developmental disorder: Pilot trial and follow-up. J Child Adolesc Psychopharmacol 7:167-179, 1997.
44. Petty RG. Prolactin and antipsychotic medications: Mechanism of action. Schizophr Res 35(Suppl):S67-S73, 1999.
45. Pollack A, McLaren EH: Serum prolactin concentration in patients taking neuroleptic drugs. Clin Endocrinol 49:513-516, 1998.
46. Rubin RT: Prolactin and schizophrenia. In: Psychopharmacology: The third generation of progress. Meltzer, HY, (ed.). New York: Raven Press, 1987, 803-808.
47. Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, Dittman, V, Chappell PB: Ziprasidone treatment of children and adolescents with Tourette's Syndrome: A pilot study. J Am Acad Child Adolesc Psychiatry 39:292-299, 2000.
48. Seeman P, Bzowej NH, Guan H-C, Bergeron C, Becker LE, Reynolds GP, Bird ED, Reiderer P, Jellinger K, Watanabe S, Toutelotte WW: Human brain dopamine receptors in children and aging adults. Synapse 1:399-404, 1987.
49. Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, Pupo-Guillen M: A study of quetiapine: Efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11:415-424, 2001.
50. Sikich L, Williamson K, Malekpour A, Bashford R, Hooper S, Sheitman B, Lieberman J: Double-blind comparison of haloperidol, risperidone and olanzapine in psychotic youth. Presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Chicago, October 1999.
51. Stiegler C, Leb G, Kleinert R, et al: Plasma levels of parathyroid-related peptide are elevated in hyperprolactinemia and correlated to bone density status. J Bone Miner Res 10(5):751-759, 1995.
52. Torring O, Isberg B, Sjoberg HE, et al: Plasma calcitonin, IGF-I levels and bone mineral density in hyperprolactinemic women during bromocriptine treatment. Acta Endocrinol 128(5):423-427, 1993.
53. Turgay A, Binder C, Snyder R, Fisman S: Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:E34, 2002.
54. Vartej P, Poiana C, Vartej I: Effects of hyper-prolactinemia on osteoporotic fracture risk in premenopausal women. Gynecol Endocrinol 15:43-47, 2001.
55. Woods SW, Martin A, Spector SG, McGlashan TH: Effects of development on olanzapine-associated adverse events J Am Acad Child Adolesc Psychiatry 41:1439-1446, 2002.
56. Wudarsky M: Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 9:239-245, 1999.
57. Yazigi R, Quintero C, Salameh W: Prolactin disorders. Fertil Steril 67:215-225, 1997.
58. Yazui-Furukori N, Kondo T, Suzuki A, Mihara K, Kaneko S: Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia. Psychopharmacology 162:63-66, 2002.